Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2020-08-30 Annual Report
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Appendix 4E Preliminary Final Report 21 pages 356.6KB
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E Preliminary Final Report Year ended 30 June 2020' and contains detailed financial statements including consolidated statements of profit and loss, financial position, cash flows, and changes in equity. It also includes directors' commentary, notes to the financial statements, and audit/review status. The reporting period is a full fiscal year ending 30 June 2020. The document is comprehensive and contains substantive financial data and analysis, not just an announcement or summary. The presence of detailed financial statements and notes indicates this is a full annual financial report. Appendix 4E is a regulatory form used in Australia for preliminary final reports, which are equivalent to annual reports or 10-K filings in other jurisdictions. Therefore, this document should be classified as an Annual Report (10-K). FY 2020
2020-08-30 English
Executive re-structure across global operations 2 pages 87.5KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 19 August 2020 regarding an executive re-structure across global operations of PYC Therapeutics. It details changes in the roles of the Managing Director and Chief Executive Officer, as well as appointments within the management team. There are no financial statements, no detailed financial performance data, no regulatory certifications, or references to voting results or capital changes. The document is a corporate announcement about management changes, which fits the category of Board/Management Information (MANG). The document length is 3241 characters, which is short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2020-08-18 English
Appointment of world-renowned Chief Scientific Officer 3 pages 97.9KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement dated 19 August 2020 about the appointment of Sue Fletcher as Chief Scientific Officer at PYC Therapeutics. It details her background, role, and the company's focus. There are no financial statements, regulatory filings, or report publications mentioned. The content is about a senior management appointment, which fits the category of Board/Management Information (MANG). The document length is 5330 characters, sufficient for a detailed announcement but not a full report. Therefore, the classification is MANG with high confidence.
2020-08-18 English
Shareholder Update August 2020 19 pages 2.5MB
Investor Presentation Classification · 95% confidence The document is titled 'Shareholder update August 2020' and contains detailed information about the company's drug development programs, leadership team, market opportunity, financial snapshot, and strategic plans. It includes forward-looking statements and disclaimers typical of investor communications. The content is structured as a presentation with slides and images (omitted here) and focuses on business updates, pipeline progress, and financial metrics rather than formal financial statements or regulatory filings. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is clearly intended to update shareholders and investors on company progress and strategy, consistent with an Investor Presentation. The length (13,526 characters) and detailed content support this classification rather than a brief factsheet or a regulatory announcement. Therefore, the most appropriate classification is Investor Presentation (IP).
2020-08-13 English
Shareholder Update - Forward View 2020 Milestones 4 pages 152.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 5 August 2020 providing a shareholder update on the forward view of 2020 milestones for PYC Therapeutics. It discusses ongoing and upcoming clinical trial preparations, drug development progress, and pipeline expansion. The content focuses on operational updates, development milestones, and forward-looking statements rather than financial results or detailed financial data. There is no indication of this being a full annual or interim report, audit report, earnings release, or regulatory filing. It is not a presentation, call transcript, or voting result announcement. The document is a corporate update aimed at shareholders and investors about progress and future plans, which fits best under the category of a general regulatory announcement or compliance update. Given the nature and length of the document, and that it does not fit other specific categories, the best classification is Regulatory Filings (RNS).
2020-08-04 English
Investor Call - 8am AWST - Wednesday 12 August 2020 2 pages 112.4KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement dated 3 August 2020, informing about an upcoming investor call scheduled for 12 August 2020. It includes details about the call, the company's drug development progress, and instructions for participation. There are no financial statements, detailed financial analysis, or comprehensive report content. The document is short (4727 characters) and serves as a notification of an event rather than a full report or transcript. It does not contain a transcript of the call, nor detailed financial data or management discussion. Therefore, it is best classified as an Investor Presentation (IP) or a Regulatory Filing (RNS). However, since it is an announcement of an investor call and not the presentation itself, and given the nature of the content, the most appropriate classification is Regulatory Filings (RNS) as a general announcement about an investor event.
2020-08-02 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.